Avandaryl (Rosiglitazone Maleate and Glimepiride) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 19, 2016 Category: Drugs & Pharmacology Source Type: news
Expensive New Diabetes Drugs Add Nothing But Cost And Complications
This is the fourth in an ongoing series of blogs exposing the rampant misuse of the medications so aggressively promoted by greedy drug companies.
I am very lucky in having the perfect partner in this truth-vs-power effort to contradict Pharma propaganda with evidence based fact.
Dick Bijl is President of the International Society of Drug Bulletins (ISDB), an impressive association of 53 national drug bulletins from all around the world, each of which publishes the best available data on the pluses and minuses of different medications.
Drug bulletins help patients and doctors see through the misleading misinformation ge...
Source: Science - The Huffington Post - November 17, 2016 Category: Science Source Type: news
Amaryl (glimepiride)
Title: Amaryl (glimepiride)Category: MedicationsCreated: 4/3/1999 12:00:00 AMLast Editorial Review: 9/16/2016 12:00:00 AM (Source: MedicineNet Diabetes General)
Source: MedicineNet Diabetes General - September 16, 2016 Category: Endocrinology Source Type: news
Amaryl (Glimepiride) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 13, 2016 Category: Drugs & Pharmacology Source Type: news
New oral diabetes drugs may also protect patients' kidney health
In a clinical trial of patients with type 2 diabetes, canagliflozin (a sodium-glucose cotransporter 2 inhibitor) slowed kidney function decline to a greater extent than glimepiride (a sulfonylurea), while having similar blood sugar –lowering effects, report investigators. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - August 19, 2016 Category: Science Source Type: news
Risk of low blood sugar differs among similar diabetes drugs
Adding sulphonylureas (SUs) to metformin remains a commonly used strategy for treating type 2 diabetes, but individual SUs differ and may confer different risks of abnormally low blood sugar, or hypoglycemia. SUs -- which include newer generation agents such as gliclazide, glipizide, glimepiride, and glibenclamide -- stimulate the production of insulin in the pancreas and increase the effectiveness of insulin in the body. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - July 19, 2016 Category: Science Source Type: news
Empagliflozin surpasses glimepiride as metformin add-on
NEW ORLEANS – When used as an add-on therapy to metformin in patients with type 2 diabetes mellitus, empagliflozin has sustained safety and efficacy in reducing in hemoglobin A1c... (Source: Clinical Endocrinology News)
Source: Clinical Endocrinology News - June 24, 2016 Category: Endocrinology Source Type: news
Warfarin, Sulfonylurea Combo Ups Severe Hypoglycemia Risk Warfarin, Sulfonylurea Combo Ups Severe Hypoglycemia Risk
The findings suggest a unique drug-drug interaction between warfarin and glipizide/glimepiride, with the greatest hypoglycemia risk at start of warfarin treatment. Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - December 21, 2015 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
Myocardial injury without electrocardiographic changes after a suicide attempt by an overdose of glimepiride and zolpidem: a case report and literature review - Chou S, Ayabe S, Sekine N.
A 40-year-old diabetic man was admitted to our hospital for poor glycemic control. During hospitalization, he took 42 mg glimepiride and 50 mg zolpidem as a suicide attempt. The following day, the creatine kinase-MB fraction and troponin I levels were elev... (Source: SafetyLit: All (Unduplicated))
Source: SafetyLit: All (Unduplicated) - November 8, 2015 Category: Global & Universal Tags: Poisoning Source Type: news
glimepiride, Amaryl
Title: glimepiride, AmarylCategory: MedicationsCreated: 4/3/1999 12:00:00 AMLast Editorial Review: 8/4/2015 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - August 4, 2015 Category: Drugs & Pharmacology Source Type: news
NPPA brings 39 more drugs under price control
The prices of formulations including Ciprofloxacin Hydrochloride, Cefotaxime, Paracetamol, Domperidone and Metformin+Glimepiride have been fixed. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - July 16, 2015 Category: Pharmaceuticals Source Type: news
NPPA fixes price of 39 drug formulation packs
As per the notification the prices of formulations including Ciprofloxacin Hydrochloride, Cefotaxime, Paracetamol, Domperidone and Metformin+Glimepiride has been fixed. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - July 15, 2015 Category: Pharmaceuticals Source Type: news
Diabetes drug is activated by light to cause pancreas to release insulin
Scientists have developed a “photoswitchable” version of the diabetes drug glimepiride that is activated through exposure to blue light, allowing insulin release by pancreatic cells to be optically controlled. Pharmaceutical Journal (Source: Society for Endocrinology)
Source: Society for Endocrinology - October 20, 2014 Category: Endocrinology Source Type: news
Empagliflozin Useful Second-Line for Diabetes vs GlimepirideEmpagliflozin Useful Second-Line for Diabetes vs Glimepiride
The SGLT2 inhibitor empagliflozin provided favorable results at 2 years compared with the sulfonylurea glimepiride when used as second-line therapy after metformin in diabetes. Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - September 17, 2014 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
Prices of 108 diabetes, cardiac formulations fixed: NPPA
The drugs that will become cheaper would include atorvastatin, gliclazide, glimepiride, heparin and metolazone among others. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - July 14, 2014 Category: Pharmaceuticals Source Type: news
